Assenagon Asset Management
MRSN

Assenagon Asset Management’s Mersana Therapeutics MRSN Stock Holding History

Assenagon Asset Management’s Portfolio MRSN Stock Details MRSN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-42,950
Closed -$6.68M – 1511
2021
Q4 		$6.68M Buy
42,950
+6,795
+19% +$1.32M 0.02% 439
2021
Q3 		$8.52M Sell
36,155
-5,483
-13% -$1.6M 0.03% 312
2021
Q2 		$14.1M Buy
+41,638
New +$15.8M 0.05% 285
2020
Q1 		– Sell
-1,371
Closed -$196K – 926
2019
Q4 		$196K Buy
+1,371
New +$100K ﹤0.01% 730
2019
Q3 		– Sell
-5,224
Closed -$529K – 987
2019
Q2 		$529K Buy
+5,224
New +$615K ﹤0.01% 843

Other funds holding MRSN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $178M AUM 118.43% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

Assenagon Asset Management's MRSN Position: Q1 2022 in Review

Assenagon Asset Management sold out of Mersana Therapeutics (MRSN) in Q1 2022, closing a stake of 42,950 shares — an estimated $6.68M sold.

Assenagon Asset Management first reported a position in MRSN in Q2 2019 and held it in 5 quarters. The position peaked at $14.1M in Q2 2021. 129 funds tracked by Wall St. Rank hold MRSN as of Q1 2022.

  • Assenagon Asset Management reported no remaining Mersana Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Assenagon Asset Management sold 42,950 Mersana Therapeutics shares in Q1 2022, an estimated $6.68M.
  • Assenagon Asset Management first reported a position in Mersana Therapeutics in Q2 2019 and held it in 5 quarters.
  • Assenagon Asset Management's Mersana Therapeutics position peaked at $14.1M in Q2 2021.
  • 129 funds tracked by Wall St. Rank held Mersana Therapeutics as of Q1 2022.

Based on Assenagon Asset Management's 13F filing for Q1 2022, filed 25 Apr 2022.